Preclinical Ex-Vivo Generation of Clinical Relevant Amounts of NK Cells from CD34+ Progenitor Cells for Immunotherapy
Jan Spanholtz(AIMM Therapeutics (Netherlands)), Harry Dolstra(Radboud University Nijmegen), Theo M. de Witte(Radboud University Nijmegen), Marleen Tordoir(Radboud University Nijmegen)
Cited by 0
Related Papers
Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022
|Bone Marrow Transplantation|2022|378
Clinical-Grade Generation of Active NK Cells from Cord Blood Hematopoietic Progenitor Cells for Immunotherapy Using a Closed-System Culture Process
|PLoS ONE|2011|239
Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients
|Clinical Cancer Research|2017|211
The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments
|Frontiers in Immunology|2017|197